Amol leads Product Development for GSK’s Cell and Gene Therapy Platform CMC group.
Amol has over 20 years of experience in Pharmaceutical and Biotech organizations. Following successful registration of Strimvelis, Amol’s group is focusing on building an autologous cell and gene therapy platform that enables the scale up and scale out of manufacturing approaches for bringing these therapies to a wider patient population. Prior to joining the cell and gene therapy group, Amol held positions of increasing responsibility within GSK’s Biopharm group and supported CMC development across the development lifecycle from pre-candidate selection to post commercial support.
Amol has a Bachelors degree in Pharmacy from the University of Bombay , Ph.D. in Pharmaceutics from The Ohio State University, and post-doctoral training from University of Iowa.